RxDoctor Payments Data

Dale Wyville

Physician Assistant · Rancho Mirage, CANPI 1528075934

Payments from drug & device makers

$962in general payments, 2019–2025

Across 30 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$228
  • Daiichi Sankyo Inc.$177
  • Takeda Pharmaceuticals U.S.A., Inc.$168
  • Novartis$118
  • Foundation Medicine, Inc.$69
  • Lilly USA, LLC$46
  • plus $156 from 7 others

What the payments were for

  • Food & beverage$94698%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962 in reported general payments places this provider in the 70th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$56,090
Medicare patients
153
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide39$553,953
JakafiRuxolitinib Phosphate25$275,863
BrukinsaZanubrutinib18$270,925
VenclextaVenetoclax13$184,365
Abiraterone Acetate40$116,231
EliquisApixaban46$30,162
Hydroxyurea31$1,297
Imatinib Mesylate18$727
Anastrozole22$692
Prednisone30$331
Dexamethasone15$276
Ondansetron OdtOndansetron13$258
Acyclovir22$238
Potassium Chloride32$210
Allopurinol23$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$21$553,95339 claims
AbbVieVenclexta$19$184,36513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →